WuXi Biologics differentiates itself from other ... in these platforms is reflected in a recent license agreement with GSK on multiple novel bi- and multispecific T-cell engager antibodies.

WuXi Biologics differentiates itself from other ... in these platforms is reflected in a recent license agreement with GSK on multiple novel bi- and multi-specific T-cell engager antibodies.

WuXi Biologics reports 32.5% North American revenue growth in 2024, driven by deals with BioNTech and Candid Therapeutics, ...

WuXi Biologics (2269.HK), a leading global CRDMO, has once again earned top recognition at the 2025 CDMO Leadership Awards, ...

To address the challenges in producing these biomolecules, WuXi Biologics has introduced the EffiX™ platform, which enables the development and manufacturing of microbial-derived biologics with ...

CORRECTION: WuXi Biologics has disputed a claim by WBJ construction has stopped at its Worcester facility. An earlier version of this article incorrectly conflated details involving WuXi Biologics ...

Shares in WuXi Biologics and WuXi AppTec have tracked up after the BIOSECURE Act – which could have profound effects on their businesses in the US – was omitted from legislation due to be ...

WUXI, China, Feb. 26, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it ...